echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Boehringer Ingelheim and Anritsu Xirong jointly developed EI-001 and completed clinical application

    Boehringer Ingelheim and Anritsu Xirong jointly developed EI-001 and completed clinical application

    • Last Update: 2021-09-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On August 23, Boehringer Ingelheim announced that the monoclonal antibody drug EI-001 developed in cooperation with Elixiron Immunotherapeutics has successfully completed the clinical application, and the Phase I human clinical trial will soon be launched in Australia
    .


    EI-001 antibodies are prepared by a single human B cells obtained technology, which is closely related to target the pathology of vitiligo, hepatitis B and the like


    Boehringer Ingelheim provided Anritsu Xirong's EI-001 project with full-process services including cell line construction, production process and formulation development, stock solution and formulation cGMP production, and CMC application document writing
    .


    The BI-HEX® CHO-K1GS cell line and its process platform used in the EI-001 project can realize early-clinical CMC development, and seamlessly connect with the high-quality requirements of late-clinical CMC development, product launch and commercial supply


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.